Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 23;127(25):3154-64.
doi: 10.1182/blood-2015-11-679902. Epub 2016 Apr 25.

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype

Julie Toubiana  1 , Satoshi Okada  2 , Julia Hiller  3 , Matias Oleastro  4 , Macarena Lagos Gomez  5 , Juan Carlos Aldave Becerra  6 , Marie Ouachée-Chardin  7 , Fanny Fouyssac  8 , Katta Mohan Girisha  9 , Amos Etzioni  10 , Joris Van Montfrans  11 , Yildiz Camcioglu  12 , Leigh Ann Kerns  13 , Bernd Belohradsky  14 , Stéphane Blanche  15 , Aziz Bousfiha  16 , Carlos Rodriguez-Gallego  17 , Isabelle Meyts  18 , Kai Kisand  19 , Janine Reichenbach  20 , Ellen D Renner  14 , Sergio Rosenzweig  21 , Bodo Grimbacher  22 , Frank L van de Veerdonk  23 , Claudia Traidl-Hoffmann  3 , Capucine Picard  24 , Laszlo Marodi  25 , Tomohiro Morio  26 , Masao Kobayashi  27 , Desa Lilic  28 , Joshua D Milner  29 , Steven Holland  21 , Jean-Laurent Casanova  30 , Anne Puel  31 ; International STAT1 Gain-of-Function Study Group
Collaborators, Affiliations

Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype

Julie Toubiana et al. Blood. .

Abstract

Since their discovery in patients with autosomal dominant (AD) chronic mucocutaneous candidiasis (CMC) in 2011, heterozygous STAT1 gain-of-function (GOF) mutations have increasingly been identified worldwide. The clinical spectrum associated with them needed to be delineated. We enrolled 274 patients from 167 kindreds originating from 40 countries from 5 continents. Demographic data, clinical features, immunological parameters, treatment, and outcome were recorded. The median age of the 274 patients was 22 years (range, 1-71 years); 98% of them had CMC, with a median age at onset of 1 year (range, 0-24 years). Patients often displayed bacterial (74%) infections, mostly because of Staphylococcus aureus (36%), including the respiratory tract and the skin in 47% and 28% of patients, respectively, and viral (38%) infections, mostly because of Herpesviridae (83%) and affecting the skin in 32% of patients. Invasive fungal infections (10%), mostly caused by Candida spp. (29%), and mycobacterial disease (6%) caused by Mycobacterium tuberculosis, environmental mycobacteria, or Bacille Calmette-Guérin vaccines were less common. Many patients had autoimmune manifestations (37%), including hypothyroidism (22%), type 1 diabetes (4%), blood cytopenia (4%), and systemic lupus erythematosus (2%). Invasive infections (25%), cerebral aneurysms (6%), and cancers (6%) were the strongest predictors of poor outcome. CMC persisted in 39% of the 202 patients receiving prolonged antifungal treatment. Circulating interleukin-17A-producing T-cell count was low for most (82%) but not all of the patients tested. STAT1 GOF mutations underlie AD CMC, as well as an unexpectedly wide range of other clinical features, including not only a variety of infectious and autoimmune diseases, but also cerebral aneurysms and carcinomas that confer a poor prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves for onset of CMC and outcome. (A) Onset of CMC. Exact age at onset of CMC was available for 253 patients. (B) Overall survival curves. Age at the time of the study was available for 269 patients. Patients with severe complications (ie, patients who displayed invasive infections, aneurysms, and/or tumors) were compared with patients without any severe complication (log-rank test, P < .001).
Figure 2
Figure 2
Photographs of patients with STAT1 GOF mutations. (A) Thrush. (B-C) Onycomycosis. (D-F) Cutaneous candidiasis. (G) Dermatophytes. (H) Cutaneous and genital candidiasis. (I) Cutaneous candidiasis. (J) Angular stomatitis. (K) Esophageal candidiasis. (L) Bronchiectasis. (M) Cerebral aneurysm. Complete phenotype of each patient is described in the supplemental Tables 1-3.
See this image and copyright information in PMC

Comment in

  • When the STATs are against you.
    Hambleton S. Hambleton S. Blood. 2016 Jun 23;127(25):3109-10. doi: 10.1182/blood-2016-05-715029. Blood. 2016. PMID: 27340249 No abstract available.

References

    1. Puel A, Cypowyj S, Maródi L, Abel L, Picard C, Casanova JL. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol. 2012;12(6):616–622. - PMC - PubMed
    1. Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) 2012;91(4):e1–e19. - PMC - PubMed
    1. Kisand K, Peterson P. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: known and novel aspects of the syndrome. Ann N Y Acad Sci. 2011;1246:77–91. - PubMed
    1. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361(18):1727–1735. - PMC - PubMed
    1. McGurk M, Holmes M. Chronic muco-cutaneous candidiasis and oral neoplasia. J Laryngol Otol. 1988;102(7):643–645. - PubMed

Publication types

Substances